{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025877","form_type":"8-K","ticker":null,"cik":"0001604477","company_name":"SQZ Biotechnologies Co","filed_at":"2022-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.379673+00:00","generated_at":"2026-06-21T11:40:46.325276+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"SQZ Biotechnologies Focuses on eAPC Program, Cuts Workforce 60%, CEO Sharei Steps Down","bullets":["Workforce reduction of approximately 60%, expected to be substantially completed in January 2023.","Estimated restructuring costs of $5 million for severance and employee-related benefits.","CEO Armon Sharei stepped down effective Nov 30, 2022; Howard Bernstein appointed Interim CEO.","CFO Micah Zajic to step down Dec 31, 2022; Richard Capasso named principal financial officer.","Company pauses first-generation APC, AAC, TAC programs to focus on eAPC; data readout expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025877","json":"https://secwatch.observer/filing/0000950170-22-025877.json","markdown":"https://secwatch.observer/filing/0000950170-22-025877.md","text":"https://secwatch.observer/filing/0000950170-22-025877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/0000950170-22-025877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/sqz-20221130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:40:46.325276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1883bba9e0","claim":"Armon Sharei resigned as Chief Executive Officer at SQZ Biotechnologies Co.","evidence_excerpt":"Armon Sharei, Ph.D., Chief Executive Officer and principal executive officer of the Company, has agreed to a separation of service with the Company, effective November 30, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/0000950170-22-025877-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"75fa0f5a6f","claim":"Howard Bernstein was appointed as Interim Chief Executive Officer at SQZ Biotechnologies Co.","evidence_excerpt":"Opn November 30, 2022, the Board appointed Howard Bernstein, M.D., Ph.D., a member of the Board and the former Chief Scientific Officer of the Company, as the Company’s Interim Chief Executive Officer, effective upon the November Separation Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/0000950170-22-025877-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a3b49c6f07","claim":"Micah Zajic resigned as Chief Financial Officer at SQZ Biotechnologies Co.","evidence_excerpt":"Micah Zajic, Chief Financial Officer and principal financial officer of the Company, has also agreed to a separation of service with the Company, effective December 31, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/0000950170-22-025877-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"2b1d0f0347e205e9b0f14efe342b520526dc7f92","claim":"SQZ Biotechnologies Co announced a restructuring with charges of total expenses of approximately $5 million (workforce reduction of approximately 60 percent).","evidence_excerpt":"As part of the prioritization decision, the SQZ Biotechnologies Board of Directors approved a restructuring plan which includes a workforce reduction of approximately 60 percent. The company expects to incur total expenses of approximately $5 million as a result of the restructuring plan","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604477/000095017022025877/0000950170-22-025877-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"total expenses of approximately $5 million"},{"label":"Headcount","value":"workforce reduction of approximately 60 percent"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}